EUCAST快速抗菌药物敏感性试验在中国含肠杆菌目血培养中的评估
该研究评估EUCAST快速抗菌药物敏感性试验(RAST)在中国血流感染常见肠杆菌目(大肠埃希菌和肺炎克雷伯菌)中的效率,使用六种市售抗菌药物及菌液加标血培养,8小时总体分类一致率≥90%。研究还为头孢他啶-阿维巴坦(30/20 μg)开发了暂定折点,对样本分离株分类准确率达93%。结果表明RAST可在8小时内可靠测定菌株敏感性。
要点
- EUCAST RAST可在8小时内快速测定肠杆菌目血流感染菌株的药物敏感性。
- 对六种抗菌药物的8小时总体分类一致率≥90%。
- 为头孢他啶-阿维巴坦开发的暂定折点分类准确率达93%。
核心结论
- EUCAST RAST是快速测定中国血流感染病原菌敏感性的可靠方法,8小时总体分类一致率≥90%。
- 本研究为头孢他啶-阿维巴坦开发的折点对样本分离株分类准确率达93%。
研究设计与样本
- 研究采用菌液加标血培养,评估EUCAST RAST对大肠埃希菌和肺炎克雷伯菌的检测效率。
- 评估了六种市售抗菌药物:亚胺培南(10 μg)、美罗培南(10 μg)、环丙沙星(5 μg)、左氧氟沙星(5 μg)、阿米卡星(30 μg)和甲氧苄啶-磺胺甲噁唑(1.25/23.75 μg)。
- 基于EUCAST指南开发了头孢他啶-阿维巴坦(30/20 μg)的暂定折点。
主要发现
- EUCAST RAST在8小时的总体分类一致率≥90%。
- 为头孢他啶-阿维巴坦开发的折点对研究分离株的分类准确率为93%。
关键数值与推荐
- 8小时总体分类一致率≥90%。
- 头孢他啶-阿维巴坦折点分类准确率93%。
- 使用的抗菌药物纸片含量:亚胺培南10 μg、美罗培南10 μg、环丙沙星5 μg、左氧氟沙星5 μg、阿米卡星30 μg、甲氧苄啶-磺胺甲噁唑1.25/23.75 μg、头孢他啶-阿维巴坦30/20 μg。
临床怎么用
- 可应用EUCAST RAST在8小时内临床测定血流感染病原菌的敏感性,辅助临床诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bloodstream infection (BSI) is defined by the presence of microbes in the bloodstream and has high mortality. Early antimicrobial therapy is key to treating BSI patients. Because of potential antimicrobial resistance, rapid evaluation for the most suitable antimicrobial therapy is important for appropriate treatment. In China, the current workflow of microbiological diagnosis in BSI involves blood culture, species identification, and antimicrobial susceptibility testing, which takes around 3 days. However, this delay could lead to worse symptoms. To rapidly and accurately assess antimicrobial susceptibility, in this study, we applied EUCAST rapid antimicrobial susceptibility testing (RAST) to determine the antimicrobial susceptibilities of the most frequently detected Enterobacterales sampled in China, including Escherichia coli and Klebsiella pneumoniae. Based on EUCAST guidelines, we evaluated its efficiencies with six commercially available antimicrobials, including imipenem (10 μg), meropenem (10 μg), ciprofloxacin (5 μg), levofloxacin (5 μg), amikacin (30 μg), and trimethoprim-sulfamethoxazole (1.25/23.75 μg), with bacterium-spiked blood cultures. In addition, we developed potential breakpoints for a recently introduced antimicrobial, 30/20 μg ceftazidime-avibactam, which has high potential for treating multidrug-resistant Enterobacterales. Our results showed that EUCAST RAST is a reliable method for rapidly determining the antimicrobial susceptibilities of BSI-causing bacteria in China, with an overall categorical agreement rate at 8 h of ≥90%. The breakpoints developed in this study can categorize the isolates sampled in this study with an accuracy of 93%. Results from our experiments can be applied to clinically determine the microbial susceptibility of BSI-causing bacteria within 8 h and benefit clinical diagnostics for BSI patients.
引用
- Shan Y, Hu B, Guo W, et al. Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Test for Enterobacterales-Containing Blood Cultures in China. J Clin Microbiol. 2022. PMID: 35354293. doi:10.1128/jcm.02559-21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。